Brenner J, Magill G B, Wissel P, Sordillo P P
Cancer. 1983 Oct 1;52(7):1142-5. doi: 10.1002/1097-0142(19831001)52:7<1142::aid-cncr2820520703>3.0.co;2-l.
Thirty-four patients with advanced soft tissue sarcoma were treated with a three-drug combination including vindesine sulfate (DVA), Adriamycin, and cyclophosphamide (DAC) (S9). Thirty-one patients are evaluable of whom 23 were previously untreated. Among the latter group there were six complete responses (26%) and five partial responses (22%), for a major response rate of 48%. No major responses were seen in the eight previously treated patients. The median duration of responses was 8 months. Leukopenia and peripheral neuropathy were the major complications of treatment. Gastrointestinal toxicity was mild. Adriamycin cardiotoxicity was seen in two patients. Although the overall response rate to DAC is comparable to that of other combinations, it may offer the advantages of an increased complete response rate and less gastrointestinal toxicity.
34例晚期软组织肉瘤患者接受了包含硫酸长春地辛（DVA）、阿霉素和环磷酰胺（DAC）的三药联合治疗（S9）。31例患者可评估，其中23例此前未接受过治疗。在后一组患者中，有6例完全缓解（26%），5例部分缓解（22%），主要缓解率为48%。8例此前接受过治疗的患者未出现主要缓解。缓解的中位持续时间为8个月。白细胞减少和周围神经病变是治疗的主要并发症。胃肠道毒性较轻。2例患者出现阿霉素心脏毒性。尽管DAC的总体缓解率与其他联合方案相当，但它可能具有提高完全缓解率和减少胃肠道毒性的优势。
